Rey-Bua, BeatrizCabrero, MónicaBento, LeyreMontoro, JuanBastos-Oreiro, MarianaParody, RocioYanez, LucreciaLopez-Godino, OrianaZanabili, JoudHerrera, PilarGutierrez, GonzaloPerez, AriadnaPiñana, Jose LNovelli, SilvanaCortés, MaríaSureda, Ana MariaCaballero, DoloresGarcía-Sancho, Alejandro Martín2024-10-042024-10-042022-11-18Rey-Búa B, Cabrero M, Bento L, Montoro J, Bastos-Oreiro M, Parody R, et al. Allogeneic Hematopoietic Stem Cell Transplantation in Transformed Follicular Lymphoma (tFL): Results of a Retrospective Multicenter Study from GELTAMO/GETH-TC Spanish Groups. Cancers (Basel). 2022 Nov 18;14(22):5670.2072-6694http://hdl.handle.net/20.500.13003/18685https://hdl.handle.net/20.500.12105/23376Background: Transformation of follicular lymphoma into an aggressive lymphoma (tFL) worsens the prognosis and the standard treatment is not completely defined. Allogeneic hematopoietic stem cell transplantation (alloSCT) could be a potentially curative option for these patients, but it has not been widely explored. Methods: We designed a retrospective multicenter study to analyze the efficacy and toxicity of alloSCT in tFL patients and potential prognostic factors of survival. Results: A total of 43 patients diagnosed with tFL who underwent alloSCT in 14 Spanish centers between January 2000 and January 2019 were included. Median age was 44 (31-67) years. After a median follow-up of 58 months, estimated 5-year overall survival (OS) and progression-free survival (PFS) were both 35%. Estimated 100-day and 1-year non-relapse mortality (NRM) were 20% and 34%, respectively. The type of conditioning regimen (3-year OS of 52% vs. 20%, respectively, for reduced-intensity vs. myeloablative conditioning) and development of chronic graft versus host disease (cGVHD) (3-year OS of 75% vs. 40%) were the only factors significantly associated with OS. The only variable with an independent association with OS was cGVHD (HR, 3.4; 95% CI, 1.2-9.6). Conclusions: Our results indicate that alloSCT continues to be a potentially curative option for patients with tFL.enghttp://creativecommons.org/licenses/by/4.0/research articleAttribution 4.0 International36428762142210.3390/cancers14225670Cancersopen access2-s2.0-85142534780887056600001L2020231296